The latest international news, analysis and features on the HIV epidemic from AVERT. Share your views and expertise with your peers in the comments box below the articles.
Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.
As we mark the 29th World AIDS Day, Sarah Hand says that with enough commitment, political will and funding we have the tools to achieve UNAIDS’ ambitious fast track targets – but only if we recognise the need for a new approach to HIV prevention.
Drug policy based on prohibition hasn't worked. It's time to build on the success of partial-decriminalisation models with an emphasis on health and human rights, says new report.
The game-changing drug, Truvada – the only drug approved for PrEP – will be offered to groups considered at risk of HIV.
We count down the top five things that everybody should know about HIV - from AIDS, to testing, to symptoms, to treatment.
Despite a willingness of men to undergo voluntary medical male circumcision (VMMC) for HIV prevention benefits in sub-Saharan Africa, uptake is low with just 56% of the 20.8 million circumcisions by 2016 target met.
The European Commission has given pharmaceutical company, Gilead, the green light to market Truvada as pre-exposure prophylaxis (PrEP) across the region.
An updated adherence analysis from the ASPIRE study indicates that consistent users of a vaginal ring containing dapivirine experienced 65% fewer infections, the 21st International AIDS Conference in Durban, South Africa heard last month.
Heightened concerns regarding the link between the hormonal contraceptive, Depo-Provera, and the risk of HIV acquisition in women after new systematic review released.